Recover faster. Age slower.

Yes — for most peptide protocols. Sermorelin specifically requires an IGF-1 baseline; other peptides may need a comprehensive metabolic panel and inflammation markers. The Men's Optimization Panel ($170, 69 biomarkers including IGF-1) is the most common starting point for Sermorelin candidates. If you already have recent labs you can upload them during intake. Lab costs are not included in the program fee — they're billed separately. Additional charges apply.

It depends entirely on the specific peptide and formulation. Sermorelin has been FDA-approved for clinical use since 1990 and is broadly accessible. BPC-157 and TB-500 were placed in FDA Category 2 in 2023, restricting routine 503A compounding. Topical or oral formulations of certain peptides may still be accessible. Your provider will explain which protocols are legally available and appropriate for your goals during intake. Peptide regulatory status changes — what we offer reflects current legal compliance.

Not all peptides have the same level of clinical evidence or regulatory standing. We group them honestly:

Tier 1 (Established) — peptides with decades of clinical use and strong evidence base, like Sermorelin.

Tier 2 (Emerging) — peptides with active human research and growing evidence, including NAD+ and Glutathione.

Investigational — peptides under FDA Category 2 restrictions (BPC-157, TB-500) where evidence is primarily animal-based and access is limited. We're transparent so you can make an informed decision.

Sometimes, when medically appropriate. For example, Sermorelin paired with testosterone (from our Hormone Optimization program) is a common combined protocol. NAD+ alongside other recovery peptides is another. But peptides are not supplements — stacking them indiscriminately is not recommended. The licensed provider will recommend which combinations make sense for your goals and which to avoid.

Pricing reflects the actual cost of the active ingredient, the complexity of compounding, the dosing frequency, and any required monitoring. BPC-157 and NAD+ protocols typically run higher because the raw materials are more expensive and the regulatory pathway is more involved. Sermorelin and Glutathione are more accessible. Your program price includes the medication, provider visits, fulfillment, and quarterly lab review. Shipping is a separate add-on, billed per order ($20 flat rate nationwide); any additional lab work is billed separately.

Varies by peptide and goal. Sermorelin: most users notice improved sleep within 6-12 weeks, body composition changes at 3-6 months. BPC-157 protocols (where accessible) typically show effects within 2-6 weeks for tissue-specific concerns. NAD+ supplementation effects on energy and mental clarity are often reported within 2-4 weeks. Glutathione effects are typically gradual and tied to oxidative stress markers measured via lab work.

If your evaluation suggests peptide therapy isn't appropriate, you won't be charged for any prescription or program fee. The provider may recommend alternative approaches — supplement protocols (no prescription required), Hormone Optimization, lifestyle interventions, or simply additional lab work to clarify the picture. Honest "no" answers are part of why this is a medical practice and not a vending machine.

It varies significantly by peptide, and we think you should know that before starting. Sermorelin, a growth-hormone-releasing analog, has the longest clinical track record of the therapies we offer. NAD+ and glutathione have a growing but still limited body of human evidence, much of it focused on specific clinical contexts rather than general "longevity." BPC-157 and TB-500 (our "Wolverine" protocol) are supported largely by animal and laboratory studies and anecdotal reports — robust human clinical trial data is lacking. None of these compounded peptides is FDA-approved, and their benefits for longevity, recovery, or anti-aging have not been evaluated or confirmed by the FDA. We present them organized by evidence and access level so you can make an informed decision with your provider rather than treating all peptides as equivalent.

Because peptides are compounded and not FDA-approved, their full safety profiles — especially with long-term use — are not as well characterized as approved medications, and unknown risks may exist. Reported and potential effects include injection-site reactions (redness, swelling, irritation), headache, fatigue, flushing, nausea, water retention, and changes in blood sugar; sermorelin and other GH-axis peptides may affect insulin sensitivity and are generally avoided in people with active cancer. BPC-157 and TB-500 are research-status compounds that are not approved for human therapeutic use, and their long-term human safety is not established. Peptide therapies may include compounded or investigational products and are offered only when legally available and judged clinically appropriate by a licensed provider after review of your history and medications. This is not a complete list of risks — discuss them with your provider and report any concerning symptoms promptly.